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Bisphosphonates are bone-specific drugs, which inhibit bone
resorption by inhibiting osteoclast activity (Fleisch, 1995).
Bisphosphonates significantly prevent bone loss and osteoporotic
fractures in postmenopausal women (Storm et al, 1990; Watts et al,
1990; Harris et al, 1993; Liberman et al, 1995; Black et al, 1996;
Karpf et al, 1997; Cummings et al, 1998; Hosking et al, 1998).
Tamoxifen has an oestrogen-agonistic effect on bone and therefore
also prevents bone loss in postmenopausal women (Love et al,
1992; Ward et al, 1993; Kristensen et al, 1994; Grey et al, 1995;
Powles et al, 1996). Women with breast cancer are usually recom-
mended to discontinue previous HRT due to the fear of increasing
the risk of breast cancer recurrence. In healthy postmenopausal
women bone loss increase after withdrawal of HRT (Lindsay et al,
1978; Christiansen et al, 1981). No data are available as to whether
antioestrogen therapy or bisphosphonates are effective enough to
inhibit the accelerated bone loss occurring after withdrawal of
HRT. 
Toremifene is a close analogue to tamoxifen with demonstrated
efficacy in advanced breast cancer (Valavaara et al, 1988). There
are 2 studies available on the effect of toremifene on bone mineral
density. In our previous report of 2 year antioestrogen therapy the
2 antioestrogens, tamoxifen or toremifene, similarly prevented the
bone loss (Saarto et al, 1997b). In another study with a lower dose
of toremifen tamoxifen was superior to toremifene (Marttunen 
et al, 1998). 
We have earlier demonstrated in a prospective, open random-
ized study, that adding clodronate treatment to adjuvant anti-
oestrogen therapy significantly improved BMD in postmenopausal
women (Saarto et al, 1997b). We here present (1) the 5-year
follow-up results of this study and (2) the impact of previous HRT
on bone loss. 
MATERIAL AND METHODS 
Patients 
The study population consists of 61 postmenopausal patients with
primary operable breast cancer and histologically proven axillary
metastases. Patients were treated between March 1991 and July
1993 at Helsinki University Hospital, Department of Oncology.
Exclusion criteria included the following: (1) age above 75 years;
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Summary In this study we report bone mineral density (BMD) changes during clodronate and antioestrogen treatment in women with breast
cancer having discontinued hormone replacement therapy (HRT) at the time of operation compared to women who had not used HRT
immediately before the operation. 61 postmenopausal women with operable breast cancer were treated with the adjuvant antioestrogen
tamoxifen 20 mg or toremifene 60 mg daily for 3 years. All patients were randomized to clodronate (1.6 g daily orally) or control groups for 3
years. 23 patients had recently (recent users) and 38 never or not for at least 1 year before operation used HRT (non-users). BMD of lumbar
spine and femoral neck were measured before antiresorptive therapy (antioestrogens and clodronate) and at 1, 2, 3 and 5 years thereafter.
All patients were disease-free at the time of BMD measurements. Patients who had recently used HRT had more significant bone loss as
compared to HRT non-users at 3 years in lumbar spine – 3.0% vs. + 1.2% (P < 0.001), but not in femoral neck – 0.4% vs. + 1.7% (P = 0.27).
Adding 3-year clodronate treatment to antioestrogen therapy improved BMD marginally at 3 years: lumbar spine + 1.0% vs. –1.7% (P = 0.01)
and femoral neck + 2.4% vs. –0.4% (P = 0.12). This was also seen at 5 years of follow-up, 2 years after termination of the antiresorptive
therapy: HRT recent users vs. HRT non-users in lumbar spine –6.5% vs. +0.5% (P < 0.0001) and in femoral neck –4.8% vs. –1.5% (P = 0.38);
and clodronate vs. controls in lumbar spine –1.0% vs. –3.2% (P = 0.06) and in femoral neck –0.1% vs. –5.2% (P = 0.001, respectively). The
type of endocrine therapy (tamoxifen and toremifene) had no significant influence on BMD changes. We conclude from this study that
postmenopausal women who have recently discontinued HRT experience more rapid bone loss than HRT non-users. Neither 3-year
antioestrogen therapy alone nor antioestrogen together with clodronate could totally prevent the bone loss related to HRT withdrawal in
lumbar spine, even though clodronate seemed to retard it. © 2001 Cancer Research Campaign http://www.bjcancer.com
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nancies; (4) breast cancer recurrence at the time of BMD measure-
ments or skeletal metastases within 6 months after the
measurement of BMD; (5) previous diseases or medications
having an influence on bone metabolism. 
Informed consent was obtained from all participants. The study
was approved by the Local Ethical Committee, at the Department
of Oncology, Helsinki University Hospital. Of the 121 eligible
patients, data from 60 patients were excluded from the analyses:
33 due to death, 11 due to breast cancer recurrence, 3 due to
protocol violation (patients treated with chemotherapy), 1 patient
due to loss from follow-up, 7 because of diseases or medications
affecting calcium and bone metabolism and 5 because of missing
data of previous HRT. Thus, 61 patients were eligible for analyses.
3 patients interrupted clodronate treatment after a median of 16
months and 2 patients had dose reduction. 2 patients interrupted
tamoxifen therapy after a median of 14 months. All these patients
are included in the analyses. 
23 women had used HRT until the breast operation (recent
users), 38 patients had not used HRT (non-users), either never (27
patients) or discontinued at least 1 year before the study entry (11
patients). The mean duration of menopause was 10 years in HRT
non-users (from 0.5 to 27 years). Pretreatment characteristics of
the subjects in the HRT recent users and non-users, and in the
clodronate and control groups are given in Table 1. Women who
had not used HRT were significantly older and heavier than HRT
recent users (P = 0.013 and 0.001, respectively). 
Treatment and follow-up 
All patients underwent surgery with axillary evacuation and total
mastectomy or breast-conserving resection and postoperative
radiotherapy. Patients were randomly allocated to receive adjuvant
antioestrogen therapy: tamoxifen 20 mg or toremifene 60 mg per
day for 3 years. In addition all patients were randomized to oral
clodronate (Bonefos®, Leiras) 800 mg twice daily for 3 years or
controls. 
Staging investigations for breast cancer included clinical exam-
ination, liver ultrasound, chest X-ray and bone scintigraphy. Basic
laboratory tests before randomization included a complete blood
count and sedimentation rate, liver enzymes (transaminase, alka-
line phosphatase, 5-nucleotidase), serum creatinine, calcium and
electrolytes. Patients were interviewed regarding menopausal
status, medications, and other diseases before randomization and
at 1, 2, 3 and 5 years thereafter. Bone scintigraphy, and determina-
tions of plasma FSH, LH and oestradiol were performed before
treatment and at 1, 2, 3 and 5 years. Plasma concentrations of FSH
and LH were measured by immunofluorometric assays (IFMA,
Wallac, Turku, Finland) and plasma oestradiol levels were
measured by a radioimmunoassay (RIA, Farmos, Oulunsalo,
Finland). Clinical investigation and basic laboratory tests were
repeated every 4 to 6 months with a radiological examination if
necessary. The minimum follow-up time was 5 years in all
patients. 
Bone densitometry 
BMD (g/cm2) was measured by DXA using a Hologic QDR-1000
densitometer (Hologic, Inc, Waltham, MA). BMD was measured
at the lumbar vertebrae (L1–L4) and femoral neck in the right
femoral area before initiation of therapy and at 1, 2, 3 and 5 years
thereafter. The coefficients of variation for precision of the BMD
measurments in the lumbar vertebrae and femoral neck were 0.9%
and 1.2%, respectively. 
Statistical methods 
The influence of different parameters on the changes from start to
those of 5-year follow-up of BMD were tested by multivariate
regression analyses with backward, stepping elimination of
nonsignificant variables: age, weight, clodronate treatment,
previous HRT and the type of endocrine therapy (tamoxifen and
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Table 1 Pretreatment characteristics (mean and (SD), median and range, or absolute number and percentage) of patients in clodronate and control groups,
and in hormone replacement therapy recent users and non-users 
Control Clodronate P value Non-users Recent users P value 
Number of patients 32 29 38 23 
Age (y) 61 (7) 58 (7) NS 62 (7) 57 (7) 0.013 
Antoestrogen: 
Tamoxifen 16 50% 16 55% NS 19 50% 13 56% NS 
Toremifene 16 50% 13 45% 19 50% 10 44% 
Study treatment: 
Controls 18 47% 14 61% NS 
Clodronate 20 53% 9 39% 
HRT: 
non-users 18 56% 20 69% NS NS 
recent users 14 44% 9 31% 
Weight (kg) 70 (12) 68 (8) NS 72 (10) 65 (8) 0.001 
Height (cm) 163 (5) 165 (5) NS 164 (5) 163 (4) NS 
FSH (U l-1) 62 15–109 51 2–100 NS 51 2–94 62 17–109 NS 
LH (U l-1) 34 14–94 35 1–89 NS 30 1–62 48 12–94 0.006 
Oestradiol (nmol l-1) 0.02 0.02–0.28 0.02 0.01–0.66 NS 0.03 0.01–0.66 0.02 0.02–0.18 NS 
Lumbar spine BMD (g/cm2) 0.970 (0.149) 0.950 (0.139) NS 0.950 (0.144) 0.975 (0.143) NS 
Normal BMD (³ 0.960 g/cm2) 11 34% 10 34% 13 34% 9 39% 
Osteopenia (0.790–0.959 g/cm2) 19 60% 17 59% 22 58% 13 57% 
Osteoporosis (< 0.790 g/cm2) 2 6% 2 7% 3 8% 1 4% 
Femoral neck BMD (g/cm2) 0.783 (0.134) 0.768 (0.119) NS 0.771 (0.136) 0.775 (0.111) NS toremifene). The effect of the independent factors were thereafter
tested by a repeated measures ANOVA model using the programs
SPSS for Macintosh, with change from baseline BMD as the
dependent variable, and with clodronate, HRT and age (above or
below median) as grouping variables. No significant interactions
between the prognostic factors were found. BMD values are
expressed as a percentage of the baseline value. Nonadjusted
percentage changes in BMD are shown in the text and tables, and
adjusted changes in the figures. Ninety-five percent confidence
intervals were calculated for the main nonadjusted outcome
measures. Other comparisons were accomplished using the
Mann–Whitney test, Chi-Square test or the Wilcoxon matched pair
test. 
RESULTS 
Regression analyses 
Age (P = 0.001), clodronate treatment (P = 0.005) and previous
HRT (P = 0.03) were independent prognostic factor of BMD
changes in lumbar spine during the 3-year treatment period, but
none in changes of femoral neck. During the whole 5 years 
follow-up age (P < 0.00001), previous HRT (P = 0.004) and
clodronate treatment (P = 0.03) were independent prognostic
factor for BMD changes in lumbar spine; and clodronate (P =
0.0008) and age (P = 0.01) for femoral neck BMD. The type of
endocrine therapy (tamoxifen and toremifene) or weight had no
significant effect on BMD changes. 
The effect of previous HRT on BMD 
In recent users of HRT there was more significant bone loss in
lumbar spine –3.0% (–5.1 to –0.9) than in HRT non-users +1.2% 
(–0.2 to +2.6) at 3 years (P < 0.0001). No significant differences
were found in femoral neck between the groups at 3 years: –0.4%
(–3.6 to +2.8) vs. + 1.7% (–0.3 to +3.7), respectively (P = 0.27). At
the end of 5 years follow-up, 2 years after finishing all antiresorp-
tive treatment, the changes from baseline were +0.5% (–1.3 to
+2.3) in the lumbar spine and –1.5% (–3.6 to +0.6) in the femoral
neck in HRT non-user, while in HRT recent users the respective
changes were –6.5% (–9.4 to –3.6) and –4.8% (–8.4 to –1.2). The
total differences between the HRT non-users and recent users in
BMD of lumbar spine and femoral neck at five years were 7.0%
Antioestrogens, clodronate and bone loss 1049
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Figure 1 Age and clodronate adjusted changes from baseline to 5 years in
BMD of lumbar spine and femoral neck in HRT non-users (plain line) and
HRT recent users (bold line) 
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Figure 2 Age and previous HRT adjusted changes from baseline to 5 years
in BMD of lumbar spine and femoral neck in the clodronate (bold line) and
the control (plain line) groups 
Table 2 Percentile changes (mean and 95% CI) from baseline in BMD of lumbar spine and femur at 3 years in the clodronate
and control groups according to previous HRT 
BMD HRT non-users HRT recent users HRT non-users HRT recent users 
at 3 years at 5 years 
Lumbar spine 
Control 0.0% –3.8% –0.2% –7.1% 
(–1.9 to +1.9) (–6.3 to –1.3) (–2.8 to +2.4) (–11.5 to –2.7) 
Clodronate +2.3% –1.8% +1.0% –5.5% 
(+0.4 to +4.2) (–6.3 to +2.7) (–1.6 to +3.6) (–9.8 to –1.2) 
Femoral neck 
Control +1.2% –2.3% –3.0% –8.1% 
(–1.8 to +4.2) (–5.4 to +0.8) (–6.6 to +0.6) (–11.5 to –4.7) 
Clodronate +2.2% +2.5% –0.2% +0.2% 
(–0.6 to +5.0) (–4.5 to +9.5) (–2.8 to +2.4) (–6.6 to +7.0) and 3.3% in favour of HRT non-users (P < 0.0001 and 0.38,
respectively) (Figure 1). 
The effect of clodronate on BMD 
During clodronate treatment there was no significant bone loss in
lumbar spine +1.0% (–0.9 to +2.9) and femoral neck +2.4% (–0.4
to +5.0) as compared to the controls –1.7% (–3.3 to –0.1) and 
– 0.4% (–2.5 to +1.7) at 3 years (P = 0.01 and 0.12, respectively).
After 5 years from the beginning of the study, 2 years after
finishing the treatment, there was still less bone loss in the
clodronate than in the control group, especially in femoral neck:
lumbar spine –1.0% (–3.4 to +1.4) vs. –3.2% (–5.8 to –0.6), and
femoral neck –0.1% (–2.6 to +2.4) vs. –5.2% (–7.7 to –2.7) (P =
0.06 and 0.001, respectively) (Figure 2). This was seen especially
in HRT non-users (Table 2). 
The effect of different antioestrogens on BMD 
No differences were found in BMD of lumbar spine and femoral
neck at 3 years between the tamoxifen and toremifene groups in
patients treated with antioestrogen only: bone loss in lumbar spine
–2.3% (–4.9 to +0.3) and –1.0% (–3.1 to +1.1) and in femoral neck
0% (–3.8 to +3.8) and –0.7% (–3.2 to +1.8) at 3 years, respec-
tively. However, there were somewhat more HRT recent users in
the tamoxifen group than in the toremifene group. 
DISCUSSION 
Our results indicate that among postmenopausal women who
discontinue HRT because of breast cancer, withdrawal of HRT is
associated with more rapid bone loss than in those women who
have not used HRT at least within a year before the adjuvant
therapy. This was seen especially in the lumbar spine, where the
bone loss rate after withdrawal of HRT was more significant than
in the femoral neck due to more rapid bone turnover rate in trabec-
ular bone than in cortical bone. Neither antioestrogen therapy
alone nor antioestrogen with clodronate could totally prevent the
bone loss related to withdrawal of HRT especially in lumbar spine.
However, addition of clodronate to the antioestrogen therapy
seemed to retard the bone loss rate more than antioestrogen alone. 
Despite the limited sample size and the retrospective nature of
the study, the study arms were well balanced except for age and
weight. Patients who had recently used HRT were significantly
younger and weighed less than those women who had not used
HRT at least within a year before breast cancer treatment, which
may have exaggerated the negative effect of previous HRT on
BMD changes. In regression analyses age but not weight had a
significant effect on BMD changes. However, after adjusting the
data by age and clodronate treatment the previous HRT still had a
significant effect on BMD changes especially in lumbar spine. 
Oestrogen withdrawal in postmenopausal women is known to
induce bone loss. In 2 previous studies of Lindsay et al (1978) and
Christiansen et al (1981) the annual bone loss of women with
mean age of 47 or 51 years was 2 to 2.5% per year during the first
3 or 4 years after the withdrawal of oestrogen replacement therapy,
slowing down within the next 4 years. Tamoxifen has been demon-
strated to prevent bone loss in HRT-naive postmenopausal women,
but in premenopausal women, on the contrary, it induces a bone
loss (Powles et al, 1996). In line with prior investigations of
tamoxifen, in the present study in patients who were treated with
antioestrogen alone, no bone loss was seen neither in lumbar spine
nor in femoral neck during the antioestrogen therapy who had not
used HRT within a year before the therapy (Love et al, 1992; Ward
et al, 1993; Kristensen et al, 1994; Grey et al, 1995; Powles et al,
1996). No data have previously been available on the bone-
maintaining effects of tamoxifen in women who have discontinued
HRT. Our reslts show that after HRT the BMD decreased both in
lumbar spine and femur despite the antioestrogen therapy. The
annual bone loss, however, during the 3-year antioestrogen
therapy seemed to be somewhat less in the present study (– 1.3%
in lumbar spine and –0.8% in femoral neck per year) than in the
previous studies without antioestrogen therapy (2.0–2.5% per
year), which might indicate a partially preventive effect of anti-
oestrogen therapy after withdrawal of HRT (Lindsay et al, 1978;
Christiansen et al, 1981). Similarly, the annual bone loss rate in the
present study during the antioestrogen therapy seems to be at the
same level as in postmenopausal women after natural menopause
(lumbar spine – 1.24 ± 1.5% and femoral neck – 0.48 ± 0.8%), but
less than in perimenopausal women (lumbar spine – 2.35 ± 1.5%
and femoral neck – 1.82 ± 1.1%) (Pouilles et al, 1993, 1995). 
The present results confirm our previous findings of 2-year
antioestrogen therapy with tamoxifen or toremifene (Saarto et al,
1997b), that the novel antioestrogen toremifene shares the partial
oestrogen agonistic effect on bone with tamoxifen. No significant
differences were found between tamoxifen and toremifene neither
in the lumbar spine nor in femoral neck with 3-year treatment. Our
results differ from those of Marttunen et al, where tamoxifen was
superior to toremifene in prevention of bone loss in 30 post-
menopausal women with primary breast cancer (Marttunen et al,
1998). This difference between the studies could be due to chance
because of small number of patients, but also due to the lower dose
(40 mg) of toremifene in their report. 
We have previously demonstrated that 2-year adjuvant
clodronate treatment improved BMD of lumbar spine and femoral
neck in postmenopausal women treated with adjuvant anti-
oestrogen therapy (Saarto et al, 1997b). At 3 years of the treatment
and even 2 years after the withdrawal of clodronate therapy BMD
was still better preserved in the clodronate group as compared to
antioestrogen alone, even though these differences were not statis-
tically significant due to limited statistical power. However, 3-year
clodronate plus antioestrogen therapy could not totally prevent the
bone loss related to HRT withdrawal especially in lumbar spine,
where the bone loss was more marked. In line with our previous
findings in premenopausal breast cancer patients with chemo-
therapy induced ovarian failure and a rapid bone loss in lumbar
spine, clodronate reduced the bone loss only partially, even though
the less marked bone loss in menstruating women was totally
prevented (Saarto et al, 1997a). Comparable studies are not avail-
able to show weather other bisphosphonates could have been more
powerful than clodronate to prevent HRT-withdrawal induced
bone loss. 
Our results indicate that postmenopausal women who have
recently discontinued HRT have more rapid bone loss than women
who have not used HRT within a year. 3-year antiresorptive
therapy with antioestrogen alone or antioestrogen and clodronate
could not totally prevent the bone loss related to HRT withdrawal
especially in lumbar spine, even though it seemed to retard it. 
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